Vine Ventures (vine.vc)
Zurich, Switzerland8
59M
7
0.12
- Stages of investment
- Areas of investment
Investor highlights
- Industry focus
- Geo focus
- Check size
- 1M — 10M
Discover reliable insights
Find relevant VC investors, identify key contacts and secure funding opportunities.
Investments analytics
Last fund
- Fund size
- USD 140000000
- Fund raised date
- 2022-06-22
Analytics
- Total investments
- 8
- Lead investments
- 0
- Follow on index
- 0.12
- Investments by industry
- Health Care (4)
- Clinical Trials (3)
- Medical (3)
- Pharmaceutical (2)
- Email (2) Show 20 more
- Investments by region
- United States (4)
- France (1)
- United Kingdom (2)
- South Korea (1)
- Peak activity year
- 2021
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 3
- Avg. valuation at time of investment
- 714K
- Group Appearance index
- 0.88
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Space Vision | 15 Dec 2023 | Advertising, Service Industry | Seed | Seoul, Seoul-t'ukpyolsi, South Korea |
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Enodia Therapeutics , a Paris, France-based biotechnology company developing novel small-molecule therapies for targeted protein degradation at the point of synthesis | Aug 1, 2026 | Biotechnology, Drug Discovery, Machine Learning | Early stage | 25000000 USD | France-based biotechnology company, a Paris |
| Sunrise Group | Sep 25, 2025 | Digital Sleep Clinic, Hardware, Sleep Health Technology, Software | - | 29000000 USD |  Namur, |
| Elkedonia | Jun 11, 2025 | Neuroplastogen, Neuropsychiatric Conditions, Precision Medicine, Therapeutic Agents | Early stage | 11000000 EUR |  Strasbourg, |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.